2022-06-17 08:45:20
The most important activity for Promore Pharma in 2022 has been the phase IIa study with drug candidate ensereptide. The company announced earlier this week that the study participants have now completed the last clinic visit. The next step is to analyse the data, with the goal of presenting results sometime during the winter. BioStock conducted a brief interview with CSO Margit Mahlapuu.
Read the full article at biostock.se:
https://www.biostock.se/en/2022/06/last-clinic-visit-completed-in-promore-pharmas-ensereptide-study/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se